Evidence map›Paper›PMID 41319234›Full record

ArticleJournal of medicinal chemistry2025

CD160-Derived Peptide as a Bidirectional Inhibitor Toward Immune Checkpoints BTLA/HVEM and HVEM/LIGHT.

Magdalena Lipińska, Piotr Ciura, Simon Gumpelmair, Emilia Sikorska, Katarzyna Kuncewicz, Adam K Sieradzan, Peter Steinberger, Anna Wardowska, Marta Spodzieja

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Magdalena LipińskaFaculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.
Piotr CiuraFaculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.
Simon GumpelmairInstitute of Immunology, Division of Immune Receptors and T Cell Activation, Medical University of Vienna, Lazarettgasse 19, 1090 Vienna, Austria.
Emilia SikorskaFaculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.ORCID 0000-0001-7851-6371
Katarzyna KuncewiczFaculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.
Adam K SieradzanFaculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.ORCID 0000-0002-2426-3644
Peter SteinbergerInstitute of Immunology, Division of Immune Receptors and T Cell Activation, Medical University of Vienna, Lazarettgasse 19, 1090 Vienna, Austria.ORCID 0000-0001-6848-4097
Anna WardowskaDepartment of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, Medical University of Gdańsk, Smoluchowskiego 17, 80-214 Gdańsk, Poland.
Marta SpodziejaFaculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.ORCID 0000-0003-2712-0048

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BTLA and HVEM are key immune checkpoint proteins involved in regulating immune responses. Since HVEM also binds to CD160 at a site that overlaps with the BTLA binding site, CD160-derived fragments were used to design peptide inhibitors targeting this interface. Several peptides were synthesized and assessed for HVEM binding using SpS analysis, and their inhibitory activity was evaluated in ELISA and cell-based assays. One peptide, namely A5, demonstrated strong HVEM binding and effectively blocked the BTLA/HVEM interaction. Molecular docking results revealed that peptide A5 binds to HVEM not only at the BTLA interaction site but also at the region involved in LIGHT binding. Consistent with these findings, ELISA and cell-based assays confirmed that A5 effectively disrupts both BTLA/HVEM and HVEM/LIGHT complex formation. These results suggest that A5 acts as a dual inhibitor of HVEM interactions, with potential therapeutic implications for immune-related disorders.

Indexed as

Antigens, CDImmune Checkpoint InhibitorsPeptidesReceptors, ImmunologicReceptors, Tumor Necrosis Factor, Member 14Tumor Necrosis Factor Ligand Superfamily Member 14Binding SitesGPI-Linked ProteinsHumansMolecular Docking SimulationProtein BindingStructure-Activity RelationshipAntigens, CDBTLA protein, humanCD160 protein, humanGPI-Linked ProteinsImmune Checkpoint InhibitorsPeptidesReceptors, ImmunologicReceptors, Tumor Necrosis Factor, Member 14TNFRSF14 protein, humanTumor Necrosis Factor Ligand Superfamily Member 14

Identifiers

PMID41319234
PMCPMC12714101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.